ZNTL News & Events

Zentalis announced data from two posters being presented at the 2026 American Association for Cancer Research Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. The data show encouraging preclinical activity of azenosertib in triple-negative breast cancer and highlight the poor prognosis of Cyclin E1-positive ovarian cancer patients with currently available treatments in a real-world data analysis. "The preclinical data in triple-negative breast cancer being presented at AACR showed that azenosertib combinations can induce complete tumor responses in a model resistant to emerging ADC therapies, supporting the potential to broaden the impact of azenosertib beyond ovarian cancer," said Julie Eastland, CEO of Zentalis. "This includes potential development of azenosertib through differentiated combination strategies with antibody-drug conjugates and chemotherapy. As ADCs advance toward first-line use in TNBC, effective post-ADC treatment strategies represent a growing unmet need that azenosertib combinations may be uniquely positioned to fill. Our data suggest azenosertib may achieve this through multiple mechanisms - possibly resensitizing tumors to chemotherapy, enhancing the responses to ADC, and extending the duration of response - which is an exciting potential future direction for our pipeline." Preclinical evidence supports azenosertib as a therapeutic strategy in TNBC: TNBC cell lines showed higher Cyclin E1 expression and greater sensitivity to WEE1 inhibition compared to other breast cancer cell lines. Azenosertib monotherapy demonstrated meaningful antitumor activity across a diverse panel of 12 TNBC in vivo xenograft models. In a patient-derived xenograft model of TNBC with clinical resistance to sacituzumab govitecan, an approved topoisomerase 1 inhibitor ADC, azenosertib + enfortumab vedotin: Induced complete responses in 7 of 8 mice; 5 mice did not progress after treatment discontinuation; Prevented tumor progression in 8 of 8 mice for more than 52 days compared to 100% progression observed within 30 days with EV alone. Drove deep tumor regression in mice models refractory to sacituzumab govitecan or trastuzumab deruxtecan with large tumor volumes. Combinations of azenosertib with TOPO1i-payload ADCs enhanced both depth and duration of response compared to ADC monotherapy in ADC-naive models. Azenosertib + paclitaxel restored substantial sensitivity to paclitaxel in a model resistant to both paclitaxel and TOPO1i ADCs.

While the S&P 500 still had its best week since November, the benchmark gauge for equities closed with a small loss of Friday after a seven-day advance. Markets ended the week in a cautious holding pattern, with momentum from earlier in the week fading.Oil remains volatile as doubts grow around the durability of the Iran ceasefire as disruptions in the Strait of Hormuz persist. Meanwhile, the CPI report showed the sharpest year-over-year price increases for consumers in nearly four years, largely driven by the recent energy shock. Even with a pause in fighting, oil flows remain constrained and supply chains are still disrupted, meaning inflation pressure doesn't immediately disappear. While the ceasefire triggered a global relief rally, investors were on edge Friday as they braced for high-stakes talks being led by Vice President JD Vance this weekend.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:CoreWeaveentered into a multi-yearMeanwhile, Anthropic is exploring designing its own AI chips,TSMCreported ain March net revenueMumbai-based Sun Pharmaceutical Industries has decided to proceed with a binding offer of $12 B for Organon,March's consumer inflation rateto last year, with the consensus expecting 3.4%.2. WALL STREET CALLS:Niketo Neutral at Piper SandlerShake Shackto Outperform at MizuhoServiceNowto Neutral at UBSCiti isin the application software group with six downgrades, including Autodeskand DocuSignIBMwith a Buy at Citi3. AROUND THE WEB:Nike'sinnovation chief Tony Bignell plans to leave the company, WSJ reportsYouTubehas raised prices for YouTube Premium and Music subscriptions, Variety reportsAppleplans to shut down its first unionized store in Maryland, Reuters reportsConocophillipswill evaluate oil prospects in Venezuela, Bloomberg reportsItaly is replacing Leonardochief Roberto Cingolani, Reuters says4. MOVERS:Commvaultrose after Reutersthe company is exploring a saleCars.comwas higher after announcing an increase to its buyback program and anZentalis Pharmaceuticalsgained after Guggenheimon the sharesFair Isaacfell after Barclayson the sharesRobloxwas lower after announcing the5. EARNINGS/GUIDANCE:WD-40reportedand reiterated its FY26 guidanceTecnoglassscut itsBeam GlobalreportedSimulations Plusreportedand cut its FY26 earnings guidanceLotus Technologyreported a year-over-yearINDEXES:The Dow fell 269.23, or 0.56%, to 47,916.57, the Nasdaq gained 80.48, or 0.35%, to 22,902.89, and the S&P 500 declined 7.77, or 0.11%, to 6,816.89.

The major averages were mixed near noon, with the Dow Jones Industrial Average in the red, the Nasdaq higher and the S&P little changed. Markets are ending the week in a cautious holding pattern, with momentum from earlier in the week fading.Oil is creeping higher again, hovering near the $100 per barrel level, as doubts grow around the durability of the Iran ceasefire as disruptions in the Strait of Hormuz persist. Meanwhile, the CPI report showed the sharpest year-over-year price increases for consumers in nearly four years, largely driven by the recent energy shock. Even with a pause in fighting, oil flows remain constrained and supply chains are still disrupted, meaning inflation pressure doesn't immediately disappear.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:CoreWeaveentered into awith AnthropicMeanwhile, Anthropic is exploring designing its own AI chips,TSMCreported ain March net revenueMumbai-based Sun Pharmaceutical Industries has decided to proceed with a binding offer of $12 B for Organon,March's consumer inflation ratecompared to last year, with the consensus expecting 3.4%.2. WALL STREET CALLS:Niketo Neutral at Piper SandlerShake Shackto Outperform at MizuhoServiceNowto Neutral at UBSCiti isin the application software group with six downgrades, including Autodeskand DocuSignIBMwith a Buy at Citi3. AROUND THE WEB:A rumor of a potential takeover approach regarding CommVaultwas highlighted in Ben Harrington's buyout-focused Betaville blogYouTubehas raised prices for YouTube Premium and Music subscriptions, Variety reportsAppleplans to shut down its first unionized store in Maryland, Reuters reportsConocophillipswill evaluate oil prospects in Venezuela, Bloomberg reportsItaly is replacing Leonardochief Roberto Cingolani, Reuters says4. MOVERS:Spire Globalrises after Canaccordon the sharesCars.comhigher after announcing an increase to its buyback program and anZentalis Pharmaceuticalsgains after Guggenheimon the sharesFair Isaaclower after Barclayson the sharesProPetrofalls after Goldman Sachscoverage of the stock with a Neutral rating5. EARNINGS/GUIDANCE:WD-40reportedand reiterated its FY26 guidanceTecnoglassscut itsBeam GlobalreportedSimulations Plusreportedand cut its FY26 earnings guidanceLotus Technologyreported ain Q4 revenueINDEXES:Near midday, the Dow was down 0.46%, or 221.08, to 47,964.72, the Nasdaq was up 0.29%, or 65.34, to 22,887.76, and the S&P 500 was down 0.09%, or 5.87, to 6,818.79.